Secondary Logo

Journal Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

Can pimavanserin help patients with Parkinson disease psychosis?

de la Cruz, Jennifer, MMSc, PA-C; Canal, Clinton, PhD

Journal of the American Academy of PAs: January 2019 - Volume 32 - Issue 1 - p 44–45
doi: 10.1097/01.JAA.0000547757.46299.3d
Pharmacology Consult

ABSTRACT Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis. This article discusses pimavanserin's mechanism of action, which patients are appropriate candidates for therapy, adverse reactions, and appropriate dosing.

At Mercer University in Atlanta, Ga., Jennifer de la Cruz is a clinical assistant professor in the PA program and Clinton Canal is an assistant professor in the College of Pharmacy's Department of Pharmaceutical Sciences. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2019 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website